Jan Van Acker is a global healthcare business leader, who has lived and held executive positions
in the US, Europe and Asia. He is passionate about making a difference for patients, by driving
innovation to solve complex and important healthcare challenges, and by coaching and
mentoring talented people to achieve aspirational visions even when faced with high
complexity and uncertainty.
Jan is currently focusing his energy on a few high-impact projects, such as the transformational
work in healthcare of the ARC innovation hub of the Sheba Medical Center – one of the world’s
leading hospitals -, where he is the Chief Strategy Officer of ARC Global. He is executive advisor
to several startups. And he also co-leads an access to medicines initiative at MIT’s Jameel
Poverty Action Lab, and supports access to healthcare projects at the Harvard TH Chan School
of Public Health.
Formerly, Jan was a Senior Vice-President at Merck & Co, Inc, one of the world’s leading
pharmaceutical companies. From 2018-2023 he was board member of Merck’s GHI Fund, a US
$500M evergreen fund that invests in digital healthcare solutions. From 2019-2022, he was
President of the Emerging Markets (a $5B business) where he focused on driving broad access
to Merck’s innovative cancer drug Keytruda. Prior to this, he was Chief Marketing Officer for
Merck’s global pharmaceutical business.
Throughout his career, Jan has also led various organizations that promote economic and social
development to improve public health policies. A.o. he served as chairman of the
pharmaceutical industry trade association in Belgium, where pharma is the largest export
industry, and he was also a board member of the Council of the Americas.
Jan holds master’s degrees from the Massachusetts Institute of Technology (MIT) and the MIT
Sloan School of Management in Cambridge (Boston), and he also earned a degree in
Mechanical Engineering from the University of Ghent in Belgium.

Head of Department for Organ Donation, Oslo University Hospital 

Head of Department of Anesthesia and Intensive Care and Vice Scientific Director for Clinical Research

Executive Chairman of Migdal Holding, Insurance and Finance

Giulia Goretti leads the review of clinical and organizational pathways at Humanitas through the adoption of the Value-Based Healthcare (VBHC) approach and Lean methodology.

A graduate in Management Engineering, she holds a VBHC Black Belt certification from Amsterdam and a Lean Green Belt from MIP Politecnico di Milano. She joined Humanitas in 2010 after an industrial experience in a global Continuous Improvement team, with the ambition to support hospitals in achieving excellence in outcomes and performance.

Giulia introduced Lean principles in 2010 and the Value-Based approach in 2018, making Humanitas one of the first hospitals in Italy to integrate these methodologies. Her work has contributed to two international recognitions: the Value-Based Healthcare Prize in Amsterdam in 2018 for bariatric surgery pathway redesign, and again in 2023 for innovations in pre-hospitalization processes.

She collaborates closely with clinicians and researchers, contributing to several peer-reviewed publications on Lean, VBHC, and digital innovation in healthcare.

Medical Consultant at Immunai

Dr. Klasko is an author, an entrepreneur and a believer in the creative and optimistic transformation of healthcare and higher education. He has been a health system CEO, a university president, and a dean of two medical colleges. Currently he is pursuing his passion to bridge academic health centers with the emerging world of generative AI, digital medicine and innovation. As President of Thomas Jefferson University, he directed a merger between an almost two century old health science university and a nationally ranked university for design and architecture. That merger was heralded by the Chronicle of Higher Education as one of the “few successful mergers between academic entities.” As CEO of Jefferson Health, he presided over the growth of the system from $1.5 billion to $9 billion including the acquisition of Health Partners Plan, making Jefferson the first integrated delivery and financial system in Philadelphia history and the largest health system in Philadelphia. This included a first of its kind digital “health at any address” partnership between Jefferson and leading health venture capital firms such as General Catalyst, a16z and Oak HC. He has been a board member and advisor to several AI behavioral health entities and led the Forbes Health Summit this year on the ethical and regulatory “unintended consequences” of generative AI. His most recent book, Feelin’ Alright: How the Message in the Music Can Make Healthcare Healthier uses music and creativity to tackle the biggest issues in healthcare His fifth book (with Hemant Taneja of General Catalyst) in 2021, UnHealthcare: A Manifesto for Health Assurance has become the manual for both founders and health system CEOs for merging the venture capital world with the traditional healthcare ecosystem. Dr. Klasko serves as Executive in Residence at General Catalyst, North American ambassador for Sheba Medical Center in Israel, and as CMO and Operating Partner of Abundant Partners. He is the lead independent director for Teleflex (TFX:NYSE), a multi-billion dollar medical device company. In 2022, President Biden appointed him to the National Board of Education Sciences. He serves as a member of the Founders Circle for BrightEdge, a unique impact investing arm of the American Cancer Society. Dr. Klasko is also the board chair of Opera Philadelphia and a trustee of Rosalind Franklin University and Chicago Medical School. Over the past five years he has been awarded by Fast Company as one of the “top 25 most creative people in business,” by Modern Healthcare as the “#2 most influential person in healthcare” and by Ernst and Young as the “entrepreneur of the year.” He lives in Miami and New York with his wife Colleen Wyse, a commercial model and former fashion executive with senior positions in Vogue, W and Glamour.

Chief Executive Officer of the Charitè – Universitätsmedizin Berlin

Dr. Charlotta Ljungman is a senior consultant cardiologist and associate professor at Sahlgrenska University Hospital and the University of Gothenburg, Sweden. Previously Director of the Cardiology department she now leads the Center for Precision Medicine at Sahlgrenska, driving the integration of genomics, biomarkers, and digital tools into clinical care. Her research focuses on heart failure, cardiomyopathies, and precision phenotyping, combining clinical data with proteomics and metabolomics to improve individualized diagnosis and treatment. Dr. Ljungman also contributes to national cardiovascular registries as head of the Swede-HF (the Swedish National Heart Failure Registry) advancing the translation of research into patient benefit.

CEO at Rigshospitalet in Copenhagen

Chief Executive Officer, University College London Hospitals

Chief Executive Officer of the Humanitas Group

Director Acute Clinic, Oslo University Hospital  

Dr. Avi Tsur, MD, MBA is Director of Obstetrics and Gynecology at Sheba Beyond, Chief Medical Director of ARC, and Founder of the Sheba ARC Women’s Health Innovation Center, advancing women’s healthcare through AI, telemedicine, and precision health. He received his medical and clinical training at Hadassah Medical School, Sheba Medical Center, and Stanford University, and holds an MBA in Healthcare Innovation from Reichman University. An internationally recognized leader in maternal–fetal telemedicine, Dr. Tsur has authored over 70 scientific publications and eight book chapters. He is the primary medical inventor of the Lioness device for preventing spontaneous preterm birth and co-founder of Shela Health, pioneering maternal–fetal precision medicine.

Chief Innovation, Transformation & AI
and ARC founder

Director, Sheba BEYOND

CEO and Co-Founder, Transmit Security

Purva Rawal, PhD, is an internationally recognized leader in value-based care and health policy, with over two decades of experience spanning government, academia, and the private sector. Currently, she is an advisor to the Duke Margolis Institute for Health Policy and Johns Hopkins University, and on international value-based payment implementation efforts. Most recently, she was the Chief Strategy Officer at the CMS Innovation Center. She led the implementation of a strategic vision grounded in accountability and whole, person-centered care, and oversaw its implementation across the Center.

Prior to her role at CMS, Dr. Rawal spent a decade in policy research and business strategy consulting, advising organizations on value-based payment and health system transformation. She also served as an adjunct assistant professor at Georgetown University, where she taught courses on the politics of health care and mentored students.

Earlier in her career, Dr. Rawal was a senior staff member on the Senate Budget Committee during the development of the Affordable Care Act and was an advisor to Senator Joseph Lieberman (I-CT). She began her policy career as a Christine Mirzayan Science and Technology Policy Fellow at the National Academies.

She is the author of The Affordable Care Act: Examining the Facts and has published in internationally recognized journals including, the Journal of the American Medical Association, the New England Journal of Medicine, and Health Affairs. Dr. Rawal received her B.A. and Ph.D. from Northwestern University.

Education:
1978-1985 Taipei Medical college, Taipei, Taiwan

Academic Appointment:
Professor of Medicine 2004-2012 Chang-Gung Memorial Hospital
Professor of Medicine 2012- School of Medicine, Taipei Medical University

Employment Record:
Post-Doctor
Fellowship 1993-1994 Institut Nationale de la Santé et
de la Recherche Médicale
(INSERM) Unité 246, Paris, France
Director 2003-2012 Division of Nephrology
Chang-Gung Memorial Hospital, Keelung
Director 2008-2012 Department of Internal Medicine
Chang-Gung Memorial Hospital, Keelung
Vice Superintendent 2012-2014 Taipei Medical University – Taipei Medical University Hospital
Vice Dean 2013-2014 College of Medicine, Taipei Medical University
Director 2015-2017 Management and development Center
Taipei Medical University
Superintendent 2017-2021 Taipei Medical University – Shuang Ho Hospital
Visiting Physician 2017-present Division of Nephrology
Taipei Medical University – Shuang Ho Hospital
Superintendent 2019-2020 Taipei Medical University – Hsin Kuo Min Hospital
Director 2020-2023 TMU Research Center for Urology and Kidney
Vice president 2022-2023 Taipei Medical University
President 2023-present Taipei Medical University

Other Experience:
Supervisor 2019-present Institute for Biotechnology and Medicine Industry
Board Member 2020-2023 Taiwan Organ Registry and Sharing Center
Director 2020-2023 Taiwan Hospital Association
President 2020-2023 The Transplantation Society of Taiwan
Director 2021-present Taiwan Global Healthcare Association
Chairman 2021-present Taiwan Kidney Foundation
President 2022-present Taiwan Society of Nephrology
President 2024-present Taiwan Association for Institutional Research
Board Member 2024-present Research Center for Biotechnology and Medicine Policy (RBMP)

Research Interest:
Renal Cellular Physiology and Biology
Fluid and Electrolytes disorders
Clinical Nephrology
Renal Replacement Therapy
Data management
Hospital management

Publications 325 journal articles (as attachments)

Communications 105 communications (as attachments)

Invited speech 320 invited speeches (as attachments)

Dr. Anke Diehl, M.D., M.A., is Chief Transformation Officer and Head of the Digital Transformation Unit at the University Medicine Essen (UME). As a medical doctor with broad clinical and scientific experience (neurology, psychiatry, neuroradiology and radiology), she is responsible for implementing innovative projects as part of the smart hospital’s digitization strategy. Dr. Diehl is consortial leader of the leading edge cluster for artificial intelligence in medicine “SmartHospital.NRW“ and won the „Female Doctor of the Year 2021“ award (German Medical Awards). She is not only a member of the digitization council of the National Chamber of Physicians, but represents Germany`s health IT users in our National expert panel “Interop Council”, which was installed by the German Ministry of Health to further nationwide interoperability in the usage of health data.

Jaume Duran holds a PhD in Medicine and a PhD in Philosophy. He is a specialist in Family and Community Medicine, holds an MBA from ESADE, a Master’s degree in Bioethics, and is a theologian. With more than 25 years dedicated to the management of healthcare and social services, he combines the role of Chief Executive Officer of a non-profit healthcare foundation with teaching responsibilities in various university master’s programs and at ESADE. He serves as Secretary of the Catalan Hospital Association, is a member of the Deontological Committee of the Barcelona Medical Association (COMB), and a member of the Board of Directors of the International Hospital Federation (IHF). He is also an Associate Professor and Coordinator of the University Master’s Degree in Management at UIC.

MD, Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin